Bioequivalence Study of Fixed-Dose Combination of Bempedoic Acid, Ezetimibe, and Atorvastatin Versus Individual Tablets in Healthy Subjects

The primary objective of this study is to evaluate the **bioequivalence** of a fixed-dose combination tablet compared to the individual administration of **bempedoic acid**, **ezetimibe**, and **atorvastatin** tablets. This assessment is clinically relevant as it may offer a simplified regimen for patients requiring these medications, potentially improving adherence and therapeutic outcomes. No secondary objectives are specified for this study.

The clinical trial involves a **study population** that includes both male and female participants, with an **age range** category code of 3, which typically corresponds to adults. The trial population is noted to include a **vulnerable population**, although specific details regarding the nature of this vulnerability are not provided. The sponsor has not disclosed the total number of participants involved in the study. Participants were selected without any specific **medical condition** being a requirement, indicating a focus on a generally healthy population. Lifestyle considerations such as diet, physical activity, or habits have not been specified. The sponsor has not provided detailed information on key inclusion or exclusion criteria for this trial.

The clinical trial is designed to evaluate the **bioequivalence** of a fixed-dose combination of bempedoic acid, ezetimibe, and atorvastatin compared to the individual administration of these tablets. This trial is categorized as a Phase 2 study and is expected to commence recruitment on October 24, 2025, with an estimated completion date of January 21, 2026. The study will employ a randomized, double-blind, controlled design to ensure the reliability and validity of the results. Participants will be randomly assigned to receive either the fixed-dose combination or the individual tablets, with neither the participants nor the investigators aware of the group assignments, thus maintaining the double-blind nature of the trial.

The trial will include several key study visits. Initially, a screening visit will be conducted to assess eligibility based on predefined criteria. This visit will ensure that participants meet the necessary requirements for inclusion in the study. Following successful screening, participants will be enrolled and randomized into the study groups. Throughout the trial, follow-up visits will be scheduled at regular intervals to monitor the participants' health status, adherence to the study protocol, and any potential adverse events. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The trial will conclude with an end-of-study visit, where final assessments will be conducted to evaluate the outcomes of the intervention.

The expected duration of participant involvement in the trial is approximately three months, from the initial screening to the end-of-study visit. Participants may be withdrawn from the study prematurely if they experience significant adverse effects, fail to comply with the study protocol, or choose to withdraw consent. The trial is designed to ensure the safety and well-being of participants while providing valuable data on the bioequivalence of the fixed-dose combination compared to individual tablets.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements cannot be provided.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not included in the data. As such, these aspects cannot be detailed in the context of this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to begin recruitment on October 24, 2025, with an estimated end date of January 21, 2026. The efficacy assessment will be conducted using predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The focus will be on evaluating the treatment's impact over the course of the study, adhering to the protocols typical of a Phase 2 trial. The trial's design will ensure that efficacy is assessed in a manner consistent with clinical research standards, although specific tools or instruments for efficacy assessments are not mentioned.